Posters

Photorefractive cross-linking for the correction of myopia: preliminary results of a controlled prospective clinical trial

Poster Details

First Author: M.Elling GERMANY

Co Author(s):    S. Hauschild   H. Dick                 

Abstract Details

Purpose:

To evaluate the safety and efficacy of a novel method for non-ablative refractive correction of myopia consisting of the zonal application of pulsed, accelerated corneal cross-linking with riboflavin and customized UVA treatment patterns.

Setting:

Ruhr University Eye Hospital, Bochum, Germany

Methods:

A prospective trial with treatment for myopia was undertaken. Corneal epithelium was removed. 0.1% riboflavin drops (VibeX Rapid, Avedro) were instilled onto the cornea at a rate of 2 drops per minute for 10 minutes. UVA (KXL II, Avedro) was delivered using pulsed illumination of 30 mW/cm2 irradiance in a 4 mm circular spot centered on the corneal vertex, for an energy dose of either 10 or 15 J/cm2. UCVA, BCVA, Pentacam topography, manifest refraction, and pachymetry were obtained at baseline and at 1, 3 and 6 months after treatment. Specular microscopy was obtained at baseline and 1 month postoperatively.

Results:

13 eyes of 7 patients, 2 male and 5 female, mean age 35 years (range 21-60) were followed for 6 months. Mean BCVA at baseline was 0.85 (±0.02 SD), mean MRSE -2.18 (±0.47 SD). Complete epithelial closure was obtained in all cases within 4 days. No adverse events were noted in the early postoperative period. At 1 month postoperatively mean UCVA was 0.71 (±0.11 SD), BCVA 0.84 (±0.04 SD) and mean MRSE was -0.88 (±0.59 SD) (n=13). At 3 months postoperatively, mean UCVA was 0.76 (±0.10 SD), BCVA 0.87 (±0.02 SD) and mean MRSE was -0.95 (±0.76 SD) (n=8).

Conclusions:

Preliminary results suggest that photorefractive cross-linking is a safe and effective technique for achieving predictable, non-ablative refractive correction in eyes with low myopia. However, longer follow-up and further studies are needed to confirm these findings.

Financial Disclosure:

NONE